Contribution of mass spectrometry-based proteomics to immunology

Expert Review of Proteomics

Volumn 3, Issue 6, 2006, Pages 653-664

  Hillen, Nina ^a   Stevanovic, Stefan ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

HLA; Major histocompatibility complex ligandome; Mass spectrometry; Peptide repertoire; Predict calibrate detect; Proteome; Stable isotope labeling

Indexed keywords

AMINO ACID SEQUENCE; ANTIBODY AFFINITY; ANTIGEN PRESENTATION; HUMAN; IMMUNOLOGY; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; MAJOR HISTOCOMPATIBILITY COMPLEX; MASS SPECTROMETRY; PROTEOMICS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; SERODIAGNOSIS;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS; HUMANS; IMMUNOLOGIC TECHNIQUES; LIGANDS; MASS SPECTROMETRY; PROTEOMICS;

EID: 33845882487     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.3.6.653     Document Type: Review

References (101)

1. Wasinger VC, Cordwell SJ, Cerpa-Poljak A et al. Progress with gene-product mapping of the Mollicutes: mycoplasma genitalium. Electrophoresis 16(7), 1090-1094 (1995).
2. Rammensee HG, Weinschenk T, Gouttefangeas C, Stevanovic S. Towards patient-specific tumor antigen selection for vaccination. Immunol. Rev. 188, 164-176 (2002).
3. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 422(6928), 198-207 (2003).
4. Cresswell P, Ackerman AL, Giodini A et al. Mechanisms of MHC class I-restricted antigen processing and cross-presentation. Immunol. Rev. 207, 145-157 (2005).
5. Li P, Gregg JL, Wang N et al. Compartmentalization of class II antigen presentation: contribution of cytoplasmic and endosomal processing. Immunol. Rev. 207, 206-217 (2005).
6. Snyder HL, Yewdell JW, Bennink JR. Trimming of antigenic peptides in an early secretory compartment. J. Exp. Med. 180(6), 2389-2394 (1994).
7. Serwold T, Gonzalez F, Kim J et al. ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature 419(6906), 480-483 (2002).
8. Yewdell JW. Not such a dismal science: the economics of protein synthesis, folding, degradation and antigen processing. Trends Cell Biol. 11(7), 294-297 (2001).
9. Reits E, Griekspoor A, Neijssen J et al. Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I. Immunity 18(1), 97-108 (2003). •• Elegant experiments to investigate the distribution and degradation of intracellular peptides within cytosol and nucleus and salvage by transporter associated with antigen processing (TAP) transport.
10. Princiotta MF, Finzi D, Qian SB et al. Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity 18(3), 343-354 (2003). •• This is a milestone paper which exactly quantifies protein turnover and the major steps of major histocompatibility complex (MHC) class I antigen processing with special respect to the DriP hypothesis.
11. Ben Shahar S, Komlosh A, Nadav E et al. 26S proteasome-mediated production of an authentic major histocompatibility class I-restricted epitope from an intact protein substrate. J. Biol. Chem. 274(31), 21963-21972 (1999).
12. Cascio P, Hilton C, Kisselev AF et al. 26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide. EMBO J. 20(10), 2357-2366 (2001).
13. Montoya M, Del Val M. Intracellular rate-limiting steps in MHC class I antigen processing. J. Immunol. 163(4), 1914-1922 (1999).
14. Bjorkman PJ, Parham P. Structure, function, and diversity of class I major histocompatibility complex molecules. Annu. Rev. Biochem. 59, 253-288 (1990).
15. Stevanovic S, Schild H. Quantitative aspects of T cell activation - peptide generation and editing by MHC class I molecules. Semin. Immunol. 11(6), 375-384 (1999).
16. Hickman HD, Luis AD, Bardet W et al. Cutting edge: class I presentation of host peptides following HIV infection. J. Immunol. 171(1), 22-26 (2003).
17. Weinschenk T, Gouttefangeas C, Schirle M et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res. 62(20), 5818-5827 (2002).
18. Storkus WJ, Zeh HJ, III, Salter RD, Lotze MT. Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. J. Immunother. 14(2), 94-103 (1993).
19. Falk K, Rötzschke O, Stevanovic S et al. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351(6324), 290-296 (1991).
20. Bluestone JA, Jameson S, Miller S, Dick R. Peptide-induced conformational changes in class I heavy chains alter major histocompatibility complex recognition. J. Exp. Med. 176(6), 1757-1761 (1992).
21. Solheim JC, Carreno BM, Smith JD et al. Binding of peptides lacking consensus anchor residue alters H-2Ld serologic recognition. J. Immunol. 151(10), 5387-5397 (1993).
22. Margulies DH, Ramsey AL, Boyd LF, McCluskey J. Genetic engineering of an H-2Dd/Q10b chimeric histocompatibility antigen: purification of soluble protein from transformant cell supernatants. Proc. Natl Acad. Sci. USA 83(14), 5252-5256 (1986).
23. Prilliman K, Lindsey M, Zuo Y et al. Large-scale production of class I bound peptides: assigning a signature to HLA-B*1501. Immunogenetics 45(6), 379-385 (1997).
24. Krüger T, Schoor O, Lemmel C et al. Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol. Immunother. 54(9), 826-836 (2005).
25. Falk K, Rötzschke O, Deres K et al. Identification of naturally processed viral nonapeptides allows their quantification in infected cells and suggests an allele-specific T cell epitope forecast. J. Exp. Med. 174(2), 425-434 (1991).
26. Hunt DF, Henderson RA, Shabanowitz J et al. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 255(5049), 1261-1263 (1992). •• Describes the complexity of the MHC ligandome and introduces electrospray tandem mass spectrometry for sequence analysis of MHC-bound peptides.
27. Hofmann S, Glückmann M, Kausche S et al. Rapid and sensitive identification of major histocompatibility complex class I-associated tumor peptides by Nano-LC MALDI MS/MS. Mol. Cell Proteomics 4(12), 1888-1897 (2005).
28. Macdonald W, Williams DS, Clements CS et al. Identification of a dominant self-ligand bound to three HLA B44 alleles and the preliminary crystallographic analysis of recombinant forms of each complex. FEBS Lett. 527(1-3), 27-32 (2002).
29. de Jong A. Contribution of mass spectrometry to contemporary immunology. Mass Spectrom. Rev. 17(5), 311-335 (1998).
30. Lemmel C, Stevanovic S. The use of HPLC-MS in T-cell epitope identification. Methods 29(3), 248-259 (2003).
31. Bodnar WM, Blackburn RK, Krise JM, Moseley MA. Exploiting the complementary nature of LC/MALDI/MS/MS and LC/ESI/MS/MS for increased proteome coverage. J. Am. Soc. Mass Spectrom. 14(9), 971-979 (2003).
32. Chen HS, Rejtar T, Andreev V et al. Enhanced characterization of complex proteomic samples using LC-MALDI MS/MS: exclusion of redundant peptides from MS/MS analysis in replicate runs. Anal. Chem. 77(23), 7816-7825 (2005).
33. Sickmann A, Bluggel M, Kulke M et al. Identification of major histocompatibility complex class II-associated peptides derived from freshly prepared rat Langerhans cells using MALDI-PSD and Edman degradation. Analyst 125(4), 569-573 (2000).
34. Domon B, Aebersold R. Mass spectrometry and protein analysis. Science 312(5771), 212-217 (2006).
35. Guerrera IC, Kleiner O. Application of mass spectrometry in proteomics. Biosci. Rep. 25(1-2), 71-93 (2005).
36. Dengjel J, Schoor O, Fischer R et al. Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proc. Natl Acad. Sci. USA 102(22), 7922-7927 (2005).
37. Dongre AR, Kovats S, deRoos P et al. In vivo MHC class II presentation of cytosolic proteins revealed by rapid automated tandem mass spectrometry and functional analyses. Eur. J. Immunol. 31(5), 1485-1494 (2001).
38. Hickman HD, Luis AD, Buchli R et al. Toward a definition of self: proteomic evaluation of the class I peptide repertoire. J. Immunol. 172(5), 2944-2952 (2004).
39. Gygi SP, Corthals GL, Zhang Y et al. Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proc. Natl Acad. Sci. USA 97(17), 9390-9395 (2000).
40. Southan C. Has the yo-yo stopped? An assessment of human protein-coding gene number. Proteomics 4(6), 1712-1726 (2004).
41. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell Proteomics 1(11), 845-867 (2002).
42. Corthals GL, Wasinger VC, Hochstrasser DF, Sanchez JC. The dynamic range of protein expression: a challenge for proteomic research. Electrophoresis 21(6), 1104-1115 (2000).
43. Washburn MP, Wolters D, Yates JR 3rd. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotechnol. 19(3), 242-247 (2001).
44. Gygi SP, Rist B, Griffin TJ et al. Proteome analysis of low-abundance proteins using multidimensional chromatography and isotope-coded affinity tags. J. Proteome Res. 1(1), 47-54 (2002). • Introduction of the ICAT strategy in proteome analysis for the direct quantitative comparison of proteins in sample pairs by stable isotope labelling of cysteine containing peptides.
45. Mann M, Hendrickson RC, Pandey A. Analysis of proteins and proteomes by mass spectrometry. Annu. Rev. Biochem. 70, 437-473 (2001).
46. Ellis DI, O'Hagan S, Dunn WB et al. From genomes to systems. Genome Biol. 5(11), 354 (2004).
47. Küster B, Schirle M, Mallick P, Aebersold R. Scoring proteomes with proteotypic peptide probes. Nat. Rev. Mol. Cell Biol. 6(7), 577-583 (2005). • Brilliant review on the use of proteotypic peptides for protein identification.
48. Jensen ON. Interpreting the protein language using proteomics. Nat. Rev. Mol. Cell Biol. 7(6), 391-403 (2006).
49. Mann M, Jensen ON. Proteomic analysis of post-translational modifications. Nat. Biotechnol. 21(3), 255-261 (2003).
50. Dengjel J, Rammensee HG, Stevanovic S. Glycan side chains on naturally presented MHC class II ligands. J. Mass Spectrom. 40(1), 100-104 (2005).
51. Kastrup IB, Stevanovic S, Arsequell G et al. Lectin purified human class I MHC-derived peptides: evidence for presentation of glycopeptides in vivo. Tissue Antigens 56(2), 129-135 (2000).
52. Haurum JS, Arsequell G, Lellouch AC et al. Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes. J. Exp. Med. 180(2), 739-744 (1994).
53. Engelhard VH, Altrich-Vanlith M, Ostankovitch M, Zarling AL. Post-translational modifications of naturally processed MHC-binding epitopes. Curr. Opin. Immunol. 18(1), 92-97 (2006).
54. Veenstra TD, Conrads TP, Issaq HJ. What to do with 'one-hit wonders'? Electrophoresis 25(9), 1278-1279 (2004).
55. Reinders J, Lewandrowski U, Moebius J et al. Challenges in mass spectrometry-based proteomics. Proteomics 4(12), 3686-3703 (2004).
56. Hanada K, Yewdell JW, Yang JC. Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature 427(6971), 252-256 (2004).
57. Schuler MM, Dönnes P, Nastke MD et al. SNEP: SNP-derived epitope prediction program for minor H antigens. Immunogenetics 57(11), 816-820 (2005).
58. Vigneron N, Stroobant V, Chapiro J et al. An antigenic peptide produced by peptide splicing in the proteasome. Science 304(5670), 587-590 (2004).
59. Friede T, Gnau V, Jung G et al. Natural ligand motifs of closely related HLA-DR4 molecules predict features of rheumatoid arthritis associated peptides. Biochim. Biophys. Acta 1316(2), 85-101 (1996).
60. + T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein. J. Immunol. 171(1), 219-225 (2003).
61. Tewari MK, Sinnathamby G, Rajagopal D, Eisenlohr LC. A cytosolic pathway for MHC class II-restricted antigen processing that is proteasome and TAP dependent. Nat. Immunol. 6(3), 287-294 (2005).
62. Dörfel D, Appel S, Grünebach F et al. Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro-transcribed MUC1 RNA. Blood 105(8), 3199-3205 (2005).
63. Nimmerjahn F, Milosevic S, Behrends U et al. Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy. Eur. J. Immunol. 33(5), 1250-1259 (2003).
64. Crotzer VL, Blum JS. Autophagy and intracellular surveillance: Modulating MHC class II antigen presentation with stress. Proc. Natl Acad. Sci. USA 102(22), 7779-7780 (2005).
65. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science 290(5497), 1717-1721 (2000).
66. Stoltze L, Schirle M, Schwarz G et al. Two new proteases in the MHC class I processing pathway. Nat. Immunol. 1(5), 413-418 (2000).
67. Osterloh P, Linkemann K, Tenzer S et al. Proteasomes shape the repertoire of T cells participating in antigen-specific immune responses. Proc. Natl Acad. Sci. USA 103(13), 5042-5047 (2006).
68. Luckey CJ, Marto JA, Partridge M et al. Differences in the expression of human class I MHC alleles and their associated peptides in the presence of proteasome inhibitors. J. Immunol. 167(3), 1212-1221 (2001).
69. Purcell AW, Gorman JJ, Garcia-Peydro M et al. Quantitative and qualitative influences of tapasin on the class I peptide repertoire. J. Immunol. 166(2), 1016-1027 (2001).
70. Wei ML, Cresswell P. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature 356(6368), 443-446 (1992).
71. Henderson RA, Michel H, Sakaguchi K et al. HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science 255(5049), 1264-1266 (1992).
72. Weinzierl AO, Sigurdardottir D, Rammensee HG, Stevanovic S. TAP-independent HLA ligands: characterization and quantification by differential mass spectrometry. Presented at: Conference proceedings Joint Annual Meeting of the German and Scandinavian Societies, Kiel, Germany (2005).
73. Muntasell A, Carrascal M, Alvarez I et al. Dissection of the HLA-DR4 peptide repertoire in endocrine epithelial cells: strong influence of invariant chain and HLA-DM expression on the nature of ligands. J. Immunol. 173(2), 1085-1093 (2004).
74. Bubenik J. MHC class I down-regulation: tumour escape from immune surveillance? (review). Int. J. Oncol. 25(2), 487-491 (2004).
75. Lilley BN, Ploegh HL. Viral modulation of antigen presentation: manipulation of cellular targets in the ER and beyond. Immunol. Rev. 207, 126-144 (2005).
76. Reits EA, Hodge JW, Herberts CA et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J. Exp. Med. 203(5), 1259-1271 (2006).
77. Schag K, Schmidt SM, Müller MR et al. Identification of C-met oncogene as a broadly expressed tumor-associated antigen recognized by cytotoxic T-lymphocytes. Clin. Cancer Res. 10(11), 3658-3666 (2004).
78. Schmidt SM, Schag K, Müller MR et al. Induction of adipophilin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis. Cancer Res. 64(3), 1164-1170 (2004).
79. Cox AL, Skipper J, Chen Y et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264(5159), 716-719 (1994).
80. Slingluff CL Jr, Yamshchikov G, Neese P et al. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin. Cancer Res. 7(10), 3012-3024 (2001).
81. Slingluff CL, Jr., Petroni GR, Yamshchikov GV et al. Clinical and immunologic results of a randomized Phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J. Clin. Oncol. 21(21), 4016-4026 (2003).
82. + progenitor-derived dendritic cell vaccine. Cancer Res. 61(17), 6451-6458 (2001).
83. Dudley ME, Wunderlich JR, Yang JC et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23(10), 2346-2357 (2005).
84. Pascolo S, Schirle M, Gückel B et al. A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry. Cancer Res. 61(10), 4072-4077 (2001).
85. Schirle M, Keilholz W, Weber B et al. Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. Eur. J. Immunol. 30(8), 2216-2225 (2000).
86. + T cells. J. Biol. Chem. 276(17), 13689-13694 (2001).
87. Lemmel C, Weik S, Eberle U et al. Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling. Nat. Biotechnol. 22(4), 450-454 (2004). •• Introduction of N-terminal labelling based on stable isotopes, a protocol useful for relative quantification of MHC ligands from two different sources.
88. Weinzierl AO, Stevanovic S. LC-MS based protein and peptide quantification using stable isotope labels: from ICAT in general to differential N-terminal coding (dNIC) in Special. Biotechnol. Genet. Eng. Rev. 23 (In Press) (2006).
89. Anderson L, Seilhamer J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 18(3-4), 533-537 (1997).
90. Gygi SP, Rochon Y, Franza BR, Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol. Cell Biol. 19(3), 1720-1730 (1999). • Demonstration of an insufficient correlation of protein and mRNA levels in yeast.
91. Huber M, Bahr I, Kratzschmar JR et al. Comparison of proteomic and genomic analyses of the human breast cancer cell line T47D and the antiestrogen-resistant derivative T47D-r. Mol. Cell Proteomics 3(1), 43-55 (2004).
92. Kloetzel PM, Ossendorp F. Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr. Opin. Immunol. 16(1), 76-81 (2004).
93. Yewdell JW, Schubert U, Bennink JR. At the crossroads of cell biology and immunology: DRiPs and other sources of peptide ligands for MHC class I molecules. J.Cell Sci. 114(Pt 5), 845-851 (2001).
94. Milner E, Barnea E, Beer I, Admon A. The turnover kinetics of MHC peptides of human cancer cells. Mol. Cell Proteomics 5(2), 357-365 (2006).
95. Koopmann JO, Albring J, Huter E et al. Export of antigenic peptides from the endoplasmic reticulum intersects with retrograde protein translocation through the Sec61p channel. Immunity 13(1), 117-127 (2000).
96. Harrison PM, Kumar A, Lang N et al. A question of size: the eukaryotic proteome and the problems in defining it. Nucleic Acids Res. 30(5), 1083-1090 (2002).
97. Carninci P, Kasukawa T, Katayama S et al. The transcriptional landscape of the mammalian genome. Science 309(5740), 1559-1563 (2005).
98. Buchsbaum S, Barnea E, Dassau L et al. Large-scale analysis of HLA peptides presented by HLA-Cw4. Immunogenetics 55(3), 172-176 (2003).
99. Dengjel J, Decker P, Schoor O et al. Identification of a naturally processed cyclin D1 T-helper epitope by a novel combination of HLA class II targeting and differential mass spectrometry. Eur. J. Immunol. 34(12), 3644-3651 (2004).
100. IMGT/HLA Database www.ebi.ac.uk/imgt/hla/
101. Syfpeithi, A database of MHC ligands and peptide motifs www.syfpeithi.de/